The company announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share. Source: BioSpace

The cash will allow the company to hire scientists to conduct preclinical research into a potential treatment for DMD. Source: BioSpace

Once upon a time, before the internet, you typically heard of a job through your local newspaper. Source: BioSpace

Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace

OncoSec Medical today announced the appointment of Daniel J. O'Connor as CEO of the Company. Source: BioSpace

Backed by Amgen Ventures, Fortuna Fix secured $25M in funding to push its autologous stem cell treatments for Parkinson's disease and spinal cord injuries into the clinic. Source: BioSpace

The updated data will be presented at the 2017 Society for Immunotherapy of Cancer Annual Meeting. Source: BioSpace

Nearly four months after issuing a voluntary recall of all lots of unexpired sterile drug products, Cantrell Drug Company has filed for bankruptcy. Source: BioSpace

Five Prime stock took a beating after it unintentionally released Phase Ia/Ib clinical trial of its CSF-1R antibody cabiralizumab with BMS' Opdivo (nivolumab). Source: BioSpace

Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace